Patritumab Deruxtecan

Malignant Neoplasm

Merck Sharp & Dohme LLCPhase 1/2Active

CC

45/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 33/ 100
Competitive Position: 81/ 100

Competitive context

1411 Active assets in the Malignant Neoplasm cohort.

Asset / Sponsor	Phase	Rating
Nabiximols Jazz Pharmaceuticals	Phase 3	BBB
Inno-206 M.D. Anderson Cancer Center	Phase 2	BB
Vitamin B6 M.D. Anderson Cancer Center	Phase 4	BB
PROPOFOL Hong Kong Children's Hospital	Phase 4	BB
Rivoceranib Jiangsu HengRui Medicine Co., Ltd.	Phase 4	BB

View all 50 →

Same molecule, other indications

Patritumab Deruxtecan is also rated in:

non-small cell lung carcinomaDormant

BB

Indicative ·

66 / 100

breast neoplasmDormant

B

Indicative ·

60 / 100

EGFR Exon 19 DeletionDormant

B

Indicative ·

60 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.